SAPIEN 3: Good Outcomes in Bicuspids

Courtesy of Dr. Carlos Fava.

Bicuspid aortic valves are found in approximately 2% of patients and represent the most frequent cause of aortic stenosis in young adults requiring valve replacement.

La SAPIEN 3 presenta buenos resultados en las bicúspides

Though TAVR has advanced significantly, this entity has not yet been included in the different randomized studies. At present, we have data from different reports, but no consolidation.

The study looked at the STS/ACC Registry, which included patients receiving the percutaneous valve SAPIEN 3 between June 2015 and November de 2018.

This analyzis included 81822 patients: 2726 presented bicuspid aortic valve (3.33%); the rest were tricuspid.

Bicuspid patients were more often men, younger, with fewer comorbidities and lower STS mortality score. After Propensity Score Matching, 2691 patients were left in each group, with mean age 74, 60% men and 4.9% STS.


Read also: AHA 2019 | Sapien vs Evolut: A Head-to-Head Study Seems Mandatory.


Bicuspid patients required a larger valve, regardless implantation or procedural success. At hospital level, there were no differences in mortality, but conversion to surgery, annulus rupture and stroke were more frequent in bicuspid patients.

At 30 days, there were no differences in mortality. In addition, there were elevated risks of stroke (2.5% vs 1.6%; absolute RD,0.89% [95% CI, 0.88% – 0.9%]; HR, 1.57 [95% CI, 1.06 – 2.33]) and definite pacemaker (9.1% vs 7.5%; absolute RD, 1.65% [95% CI, 1.63%-1.66%]; HR, 1.23 [95% CI, 1.02-1.49]) in bicuspid patients.

At one year, there were no differences in mortality or stroke in both groups.


Read also: TCT 2019 | Mitral Valve-in-Valve: 1-Year Results for Sapien 3 in Mitral Valve Replacement for Degenerated Bioprostheses.


There were no differences in valve hemodynamics profile at 30 days and one year in area, gradient or moderate to severe regurgitation.

Both groups improved functional class.

Conclusion

In this registry of propensity score matched patients, those receiving transcatheter aortic valve replacement for severe aortic stenosis in bicuspid or tricuspid valves showed no differences at 30 days and one year in mortality. However, there was increased stroke in bicuspid valve patients.

Given the potential bias in patient selection and the absence of a control group, these outcomes call for further study to better determine the safety and efficacy of transcatheter aortic valve replacement in bicuspid patients.

Courtesy of Dr. Carlos Fava.

Original Title: Association Between Transcatheter Aortic Valve Replacement for Bicuspid vs Tricuspid Aortic Stenosis and Mortality or Stroke.

Reference: Raj R. Makkar, et al. JAMA. 2019;321(22):2193-2202. doi:10.1001/jama.2019.7108.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...